XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 20,105 $ 13,159
Marketable securities 12,063 29,144
Accounts receivable - related party 11 588
Prepaid and other current assets 915 773
Total current assets 33,094 43,664
Property and equipment, net 264 353
Operating lease right-of-use asset 1,423 2,217
Investment in Angel Pharmaceuticals 17,072 21,877
Other assets 89 129
Total assets 51,942 68,240
Current liabilities:    
Accounts payable 1,404 1,976
Operating lease liability 1,336 1,228
Accrued and other liabilities 4,559 7,548
Total current liabilities 7,299 10,752
Operating lease liability 354 1,373
Total liabilities 7,653 12,125
Commitments and contingencies (Note 13)
Stockholders' equity:    
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock: $0.0001 par value; 290,000,000 shares authorized at September 30, 2023 and December 31, 2022; 49,038,582 and 46,553,511 shares issued and outstanding at September 30, 2023 and December 31, 2022 5 5
Additional paid-in capital 373,791 364,361
Accumulated other comprehensive loss (1,443) (563)
Accumulated deficit (328,064) (307,688)
Total stockholders' equity 44,289 56,115
Total liabilities and stockholders' equity $ 51,942 $ 68,240